Several publications or presentations in the field of sexual medicine have used erroneous terminology and methodology about nitric oxide (NO). Although these have been pointed out in the meetings or during the manuscript review processes, the corrections remained anecdotal and no written commentary can be found to lead young scientists in the field. Since one of the main aims of the International Journal of Impotence Research (IJIR) is education, I would like to draw the attention of readers to these mistakes:
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'NANC nerve'
NO is now known to be the one of the major mediators of penile erection and clitoral tumescence. We know that there are two main sources of NO in the penis and clitoris: the endothelium and nerves. These NO-producing nerves have frequently and erroneously been described as 'NANC nerves'. I would like to try to explain here what NANC means and why 'NANC nerve' is the wrong terminology: Nonadrenergic noncholinergic (NANC) neurotransmission was first described in late 19th century when atropine-resistant excitation of the bladder was demonstrated in response to pelvic nerve stimulation, 1 and relaxation of the stomach during vagal nerve stimulation was revealed following atropine treatment. 2 NANC neurotransmission leading to relaxation of the urogenital smooth muscle was first described by Gillespie in the early 1970s. 3 He showed that stimulation of intrinsic nerves in the anococcygeus and retractor penis muscles caused contraction, which could be blocked with tetrodotoxin (a nerve-blocking agent), guanethidine (an inhibitor of noradrenaline release) or alpha-1 adrenoceptor antagonists (inhibiting the effect of noradrenaline on the smooth muscle), suggesting that these contractions are mediated by neuronal release of noradrenaline. After blockade of noradrenergic contractions and elevation of the tone of the tissue, the same stimulation caused relaxation. These relaxations were not affected by either alpha-receptor or muscarinic-receptor antagonists, suggesting the existence of a NANC inhibitory neurotransmitter. In subsequent years, many endogenous substances such as vasoactive intestinal peptide and adenosine triphosphate have been suggested to be this NANC neurotransmitter. However, they did not convincingly mimic the inhibitory NANC response. In the late 1980s, similarities between endothelium-derived relaxing factor (EDRF) and the inhibitory NANC transmitter were observed. The discovery that EDRF was NO provided the evidence required for the later identification of the inhibitory NANC transmitter as NO. Today we know that NO is released as an NANC neurotransmitter in the penis and clitoris as well as many other smooth muscle structures in the body, ranging from blood vessels to the gastrointestinal tract. The term NANC therefore refers to the type of neurotransmission, not to the type of nerve. NO is an NANC neurotransmitter; however, it is released from different subsets of nerves in different tissues. In the penis and clitoris, it is now widely accepted that NO is released from postganglionic parasympathetic (cholinergic) nerves. 4 Therefore, although it may sound ironic, NO is an NANC transmitter, which is released from cholinergic nerves in the penis and clitoris. 'Nitrergic nerve' 5 or 'NO-releasing/producing autonomic nerve' are more suitable terms than 'NANC nerve' for NO-releasing nerves in the penis and clitoris.
Other NO-related terminology I would like to recommend two papers, which give basic guidelines for the standardization of NO-related terminology such as the recommended abbreviations for the isoforms, inhibitors, substrates of NO synthases (NOS) and NO donors. 5, 6 I would also like to draw attention to the selectivity of certain NOS inhibitors such as 7-nitroindazole (7-NI), which have been claimed to be specific for neuronal NOS (nNOS) in several publications in the field of sexual medicine. I would highly recommend to the readers a review by Moore and Handy, 7 which explains the relative selectivity of such compounds. Briefly, the authors suggest that 7-NI is only relatively selective for nNOS in vivo. They also comment that none of the nNOS inhibitors (including 7-NI) reach the desired 100:1 ratio for isoform selectivity in vivo.
The measurement of NOS activity
There are several ways of measuring NOS activity such as protein phosphorylation or measurement of NO by direct or indirect methods. The most commonly used method is by determining the NOS inhibitor-sensitive conversion of radiolabeled arginine to citrulline with separation of the labeled products from substrate by ion-exchange techniques; this is commonly referred to as 'the citrulline conversion assay'. I would suggest to readers a methodology review, which teaches the tricks-ofthe-trade in this assay. 8 Some incorrect applications, which have been common in the field of sexual medicine, however, deserve to be highlighted:
1. Firstly, this assay does not measure the relative enzyme activity of eNOS and nNOS, it can only differentiate calcium-dependent constitutive NOS activity (eNOS þ nNOS) from calcium-independent inducible NOS activity (iNOS). In order to make this differentiation, each sample needs to be incubated in the absence and presence of a calcium chelator (eg 1 mM EGTA). Additionally, each sample needs to be incubated in the absence and presence of a potent inhibitor of NOS in order to exclude nonspecific activity. 2. High concentrations of L-arginine, which can be found in the tissues or cells needs to be removed from the extract by a pretreatment with ionexchange resin. If this is not done, endogenous L-arginine may interfere with the assay and reduce the specific activity of the radiolabeled arginine in an uncontrolled way. 3. It should be noted that this assay does not measure the NOS activity in vivo or in situ. Once the tissue or cell is removed and the cytosol is extracted, the factors that might affect the activity of the enzyme(s) may no longer be present in the environment.
